Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04530682

COVID-19 in Rheumatic Inflammatory Diseases Under Immuno-suppressive Drugs

Sponsor: University Hospital, Montpellier

View on ClinicalTrials.gov

Summary

Accurate knowledge of the humoral immune responses induced by SARS-CoV-2 in patients undergoing immunosuppressive therapy is essential to guide recommendations for infected patients and for vaccination policy for uninfected immunosuppressed patients.

Official title: Seroprevalence and Clinical Expression of SARS-CoV-2 Infection in Patients With Chronic Inflammatory Rheumatisms and Impact of Immuno-suppressive Drugs on the Persistence of Anti-SARS-CoV2 Antibodies During Two Years of Follow-up

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

163

Start Date

2021-03-05

Completion Date

2024-02-15

Last Updated

2026-06-12

Healthy Volunteers

No

Interventions

BIOLOGICAL

Biological samples

Serum and plasma samples. At baseline, 6, 12 and 24 months

Locations (1)

Centre hopsitalier universitaire de Montpellier

Montpellier, Occitanie, France